Loading…
Benitec Biopharma Inc. is projected to rise to $15.41 by 2027, a +33% move from its current price of $11.60. BNTC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $11.34 | $11.61 | $11.88 | +0.05% |
| May 30 | $11.24 | $11.61 | $12.00 | +0.10% |
| May 31 | $11.16 | $11.62 | $12.09 | +0.15% |
| Jun 1 | $11.10 | $11.62 | $12.17 | +0.20% |
| Jun 2 | $11.04 | $11.63 | $12.25 | +0.25% |
| Jun 3 | $10.99 | $11.64 | $12.31 | +0.30% |
| Jun 4 | $10.95 | $11.64 | $12.38 | +0.35% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.95 | $11.64 | $12.38 | +0.35% |
| Week 2 | $10.71 | $11.68 | $12.74 | +0.71% |
| Week 3 | $10.54 | $11.72 | $13.03 | +1.06% |
| Week 4 | $10.41 | $11.76 | $13.30 | +1.42% |
| Week 5 | $10.30 | $11.81 | $13.54 | +1.78% |
| Week 6 | $10.20 | $11.85 | $13.76 | +2.14% |
| Week 7 | $10.11 | $11.89 | $13.98 | +2.50% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
These facts describe the core business and its focus on genetic medicines and gene-therapy initiatives, anchored by its development programs and corporate location.
Benitec Biopharma Inc. (BNTC) is the asset in the Healthcare space with a current price of $11.23 and a market capitalization of $385.8M. It is ranked 3261 by market capitalization.
The 30-day forecast outlook shows a neutral starting point for 2026, with an average price of $11.23 and a range from $10.06 to $15.45. The sentiment for 2026 is Neutral, reflecting flat near-term expectations.
Beyond 2026, the forecast turns bullish, with steadily higher average prices and rising ROIs across the horizon, culminating in substantial upside by 2050 (average $94.01 and max $166.35) as sentiment shifts to bullish in subsequent years. This implies meaningful upside potential if the longer-term forecast plays out.
A major floor 24.4% below — a decisive break under it would weaken the trend.
The nearest floor, 7.6% below — buyers have tended to step in here.
The nearest ceiling, 21.4% above — a clean break opens room to run.
A major ceiling 33.6% above — clearing it would confirm fresh momentum.
Key BNTC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BNTC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.33 | Buy | $11.40 | Buy |
| MA 10 | $11.32 | Buy | $11.45 | Buy |
| MA 20 | $11.73 | Sell | $11.65 | Sell |
| MA 50 | $11.78 | Sell | $11.80 | Sell |
| MA 100 | $11.75 | Sell | $11.98 | Sell |
| MA 200 | $12.70 | Sell | $12.23 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.20 | Neutral |
| Stoch RSI (14) | 83.22 | Sell |
| CCI (20) | -21.08 | Neutral |
| Williams %R (14) | -43.59 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -5.54 | Sell |
| Bollinger %B (20,2) | 0.43 | Neutral |
| Stochastic %K (14) | 56.41 | Neutral |
| TRIX (15) | -0.21 | Sell |
| Awesome (5,34) | -0.83 | Sell |
| Ultimate (7,14,28) | 46.10 | Neutral |
| Momentum (10) | -0.24 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 11.47 | Buy |
| ADX (14) | 13.00 | Neutral |
| ATR (14) | 0.26 | Info |
The 30-day technical picture is Bearish, with RSI(14) at 40 and near-term momentum softer.
The stock trades below the SMA50 of $11.79 and below the SMA200 of $12.71, suggesting potential for further near-term downside if support does not hold.
Key levels to watch are support at $10.72 and resistance at $14.08, with the 30-day trading range spanning $9.58 to $13.16. The asset exhibits elevated volatility, with an annualized volatility of 50%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $10.06 | $11.60 | $16.02 | 0% | Neutral | |
| $12.40 | $15.41 | $20.17 | +33% | Bullish | |
| $14.74 | $18.73 | $25.29 | +61% | Bullish | |
| $16.08 | $20.82 | $28.81 | +80% | Bullish | |
| $17.18 | $22.62 | $31.96 | +95% | Bullish | |
| $18.75 | $25.07 | $36.07 | +116% | Bullish | |
| $18.68 | $25.32 | $37.04 | +118% | Bullish | |
| $20.06 | $27.56 | $40.93 | +138% | Bullish | |
| $24.12 | $33.56 | $50.53 | +189% | Bullish | |
| $26.85 | $37.80 | $57.65 | +226% | Bullish | |
| $33.99 | $50.51 | $81.34 | +335% | Bullish | |
| $69.83 | $113.69 | $198.34 | +880% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $10.06 | $11.60 | $13.64 | +0.00% |
| June 2026 | $10.30 | $12.06 | $14.42 | +3.98% |
| July 2026 | $10.30 | $12.15 | $14.69 | +0.70% |
| August 2026 | $10.08 | $11.94 | $14.58 | -1.66% |
| September 2026 | $10.25 | $12.21 | $15.00 | +2.19% |
| October 2026 | $10.59 | $12.67 | $15.67 | +3.77% |
| November 2026 | $10.58 | $12.70 | $15.80 | +0.25% |
| December 2026 | $10.63 | $12.81 | $16.02 | +0.87% |
Click any year to see its month-by-month BNTC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The BNTC price prediction for 2026 points to an average of $11.60 (low $10.06, high $16.02) — a potential gain of 0% on today's $11.60. Price action looks broadly range-bound.
In 2027, BNTC is projected to trade between $12.40 and $20.17, averaging $15.41 — a potential gain of +33% from today's $11.60. That is up +33% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Benitec Biopharma Inc.'s 2028 outlook centres on $18.73, within a $14.74 to $25.29 range. That is up +22% on the projected 2027 average. That marks a +61% change versus current levels. Momentum favours further upside here.
By 2029, BNTC could reach as high as $28.81, with a base case around $20.82 and support toward $16.08 — roughly +80% from $11.60. Buyers look set to stay in control over this stretch.
Expect BNTC to range from $17.18 to $31.96 through 2030. The $22.62 average target implies a +95% move from current prices. That is up +9% on the projected 2029 average. Momentum favours further upside here.
The BNTC price prediction for 2031 points to an average of $25.07 (low $18.75, high $36.07) — a potential gain of +116% on today's $11.60. Buyers look set to stay in control over this stretch.
In 2032, BNTC is projected to trade between $18.68 and $37.04, averaging $25.32 — a potential gain of +118% from today's $11.60. That is up +1% on the projected 2031 average. Momentum favours further upside here.
Benitec Biopharma Inc.'s 2033 outlook centres on $27.56, within a $20.06 to $40.93 range. That is up +9% on the projected 2032 average. That marks a +138% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, BNTC could reach as high as $50.53, with a base case around $33.56 and support toward $24.12 — roughly +189% from $11.60. Momentum favours further upside here.
Expect BNTC to range from $26.85 to $57.65 through 2035. The $37.80 average target implies a +226% move from current prices. That is up +13% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The BNTC price prediction for 2040 points to an average of $50.51 (low $33.99, high $81.34) — a potential gain of +335% on today's $11.60. Momentum favours further upside here.
In 2050, BNTC is projected to trade between $69.83 and $198.34, averaging $113.69 — a potential gain of +880% from today's $11.60. That is up +125% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in BNTC today (≈ 86.206897 BNTC) could be worth
$9,800.67
+$8,800.67 (+880%) by 2050 · US Dollar
Based on the average projected BNTC price of $113.69 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BNTCwould be worth at today's price.
$1,000 invested in BNTC on May 27, 2025 (≈ 69.832404 BNTC) would be worth
$810.06
-$189.94 (-19.0%) today · 0.81× · US Dollar
Based on a BNTC entry price of $14.32 vs. today's $11.6.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $10.99 | $1,055.51 | +5.6% |
| 1 month ago | $12.61 | $919.9 | -8.0% |
| 3 months ago | $11.19 | $1,036.64 | +3.7% |
| 6 months ago | $12.96 | $895.06 | -10.5% |
| 1 year ago | $14.32 | $810.06 | -19.0% |
| All time (5.0y) ago | $79.9 | $145.18 | -85.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BNTC forecast.
Our base-case forecast reaches $23.00 around 2031.
Implied market cap at $23.00: $790.15M
Over the multi-year horizon, the forecast shows a bullish trajectory beginning in 2027 and extending through 2050. The 2027 avg is $14.48 with a 29 ROI and bullish sentiment, followed by 2028 avg $17.26 (53.7 ROI) and bullish sentiment, and 2029 avg $19.20 (71 ROI).
By 2030 the avg is $20.62 with an 83.6 ROI, and sentiment remains bullish as the path toward higher prices continues into 2031 (avg $22.38, ROI 99.3) and 2032 (avg $22.45, ROI 99.9). The forecast progresses through 2033 (avg $24.08, ROI 114.5) and 2034 (avg $28.92, ROI 157.6), then 2035 (avg $32.71, ROI 191.3).
Longer-dated projections extend to 2040 (avg $41.98, ROI 273.8) and 2050 (avg $94.01, ROI 737.2) with bullish sentiment. These figures are estimates and not guarantees; actual results may differ and depend on various factors.
Tap a question to reveal the answer.
The forecast for 2030 shows an avg of $20.62, a min of $15.56, a max of $29.35, with an ROI of 83.6 and a bullish sentiment.
Forecasts indicate bullish sentiment from 2027 onward with rising averages and ROIs (for example, 2027 avg $14.48, ROI 29; 2030 avg $20.62, ROI 83.6). The 2026 outlook is Neutral with avg $11.23. These are estimates, not guarantees.
Yes, the forecast shows higher upside in later years, with 2050 max $166.35 and 2040 max $68.40, indicating potential exceedance of $100 under the projected path.
Current price is $11.23 and market cap is $385.8M.
For 2026, the min is $10.06, avg $11.23, max $15.45, with ROI 0 and sentiment Neutral.
Benitec Biopharma Inc. Community Discussion
0Share your Benitec Biopharma Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.